Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...36373839404142434445464748»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  EASE: An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Dec 10, 2019   
    P2,  N=52, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Jun 2019 --> Dec 2018
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
    Clinical, Journal:  Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment: A case report. (Pubmed Central) -  Dec 8, 2019   
    However, symptoms were not relieved following anti-infective treatment and the patient subsequently died of respiratory failure. To the best of our knowledge, this is the first case of bronchopleural fistula associated with the use of anlotinib in a patient with squamous cell lung cancer.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open, Combination therapy, Metastases:  Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC (clinicaltrials.gov) -  Dec 3, 2019   
    P2,  N=48, Recruiting, 
    Our preclinical work indicates that anlotinib acts as a novel inhibitor of VEGFR2 and MET that blocks tumorigenesis in osteosarcoma, which could be translated into future clinical trials. Not yet recruiting --> Recruiting
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
    Enrollment open, Metastases:  Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 7, 2019   
    P1,  N=22, Recruiting, 
    miR-596 targets Survivin and enhances the antitumor effect of anlotinib on OSA cells. Not yet recruiting --> Recruiting
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  CSOAIMTOAN: Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC (clinicaltrials.gov) -  Oct 21, 2019   
    P=N/A,  N=83, Recruiting, 
    The combined treatment of nivolumab and anlotinib is likely to be considered as an optional management of advanced ESCC. Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
    Clinical, Journal:  The efficacy and safety of anlotinib treatment for advanced lung cancer. (Pubmed Central) -  Oct 17, 2019   
    In the third-line or more-line treatment of advanced lung cancer, anlotinib appears to have some activity when utilized as a salvage treatment. Adverse reactions are controllable.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker:  Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. (Pubmed Central) -  Oct 17, 2019   
    Anlotinib has been approved in advanced NSCLC by Chinese Food and Drug Administration (CFDA)...ICIs approved by the FDA and/or EMA for advanced NSCLC treatment include nivolumab, pembrolizumab, and atezolizumab...So current efforts have focused on exploring new potential combinatorial strategies with synergistic antitumor activity. Here, we summarized the theoretical basis, current clinical data, and potential future perspective of immunotherapy combined with anti-angiogenic agents for advanced NSCLC.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial initiation date, Combination therapy, Metastases:  FL-ALTER: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (clinicaltrials.gov) -  Oct 9, 2019   
    P3,  N=310, Not yet recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jun 2020 Initiation date: Aug 2019 --> Jun 2020
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
    Journal, Tumor Mutational Burden, BRCA Biomarker:  Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer. (Pubmed Central) -  Oct 9, 2019   
    Furthermore, the IDH1 mutation is identified as an unfavorable factor for anlotinib therapy under TMI-based stratification, and the TMI plus IDH1 mutation status potentially predicts response to anlotinib. Collectively, this study provides a circulating DNA sequencing-based stratification method for identifying anlotinib responders via a noninvasive approach, and thus potentially improves the clinical outcome of NSCLC patients receiving third-line therapy.